Public Company News

Lithium Australia’s innovative "Sileach" Lithium processing technology has played a crucial role in securing a joint venture in Germany that plans to extract lithium from mica for the huge European market. The German partner in the new joint venture locked in the deal after exhaustive due diligence showed Sileach was ideal for extracting lithium from their tin deposits in Europe.

When it comes to saving the lives of beach goers, there are few bigger names around the world than Bondi Rescue’s Bruce “Hoppo” Hopkins. The chief lifeguard at Bondi Beach has teamed up with WA-based Shark Mitigation Systems to promote their innovative shark detecting "Clever Buoy" technology. Hopkins first trialed the technology at Bondi in 2016.

Lithium Australia’s processing expertise has produced exceptional results from metallurgical testing of the Agua Fria Lithium clay prospect in Mexico, extracting up to 99% Lithium without roasting in just four hours. The result is a major boost for the economics of Agua Fria which is adjacent to the world’s largest known Lithium clay deposit.

Blina Minerals have moved quickly at their new Dingo Gold project in the Eastern Goldfields, with detailed geological mapping and a geochemical survey underway just a fortnight after taking control. Dingo has shallow and deeper gold targets that have not been properly drill tested and offers up significant upside on Blina’s bargain acquisition price of just $20,000.

Analytica have appointed a global heavyweight in the pharmaceutical industry to its board of directors as they gear up for the international launch of an innovative medical device that combats urinary incontinence. Dr Peter B. Corr, the former head of R&D at Pfizer, has joined the Analytica board, strengthening ties he already has as a significant shareholder.

An independent clinical trial of MGC Pharma’s cannabis-based dermatological creams has produced spectacular results with the trials showing an 80% improvement in acne prone skin, 73% improvement in psoriatic plaques, 86% improvement of irritated skin and over 70% improvement in the visual appearance of redness, dryness, flaky and oily skin conditions.

Blackham’s latest round of drilling at Wiluna has produced a best-ever result of 15.4 metres at more than 21 g/t gold, located in a new high-grade shoot that is outside the existing open-pit mine plan. The new drill results revealed much more mineralisation around the old West Pit and make a ‘super pit’ stretching up to 2km a real possibility.

PharmAust’s trials of its promising anti-cancer drug in dogs have produced encouraging early results, reducing the size of tumours in three out of four dogs with no other treatment. The early-stage trials have also shown it will be safe to give dogs significantly higher doses, which could lead to some spectacular results in the next stage of trials.

The rich geology of Hammer Metal’s ground east of Mt Isa has produced yet another happy surprise for the Perth-based explorer —graphite. A recent electromagnetic survey by helicopter highlighted a conductive, graphite-rich bed, with initial samples assaying up to 10% total graphitic carbon.

Stargroup and small tier bank, Goldfields Money, have doubled the size of their partnership, announcing that up to $30 million of Goldfields excess cash would now be made available for Stargroup ATM machines. Goldfields’ banking license coupled with Stargroup’s market penetration conjures up any number of future opportunities for the two ASX listed companies.

Perth-based CVCheck is charging into the black after continued strong revenue growth in April and May. The innovative provider of online police checks, employment screening and a burgeoning range of related products also has more growth in the pipeline, thanks in part to changes to 457 visas in Australia and new requirements by NZ’s Health Department.

Perth listed biotech PharmAust, have determined that their promising anti-cancer drug known as MPL might also be useful in the treatment of diabetes, brain disease and age related disorders. The company announced this week they have secured a patent for MPL in Australia relating to the treatment of the three newly targeted illnesses.